id:"swepub:oai:gup.ub.gu.se/91543"
Sökning: id:"swepub:oai:gup.ub.gu.se/91543" > Effect of candesart...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04710naa a2200781 4500 | |
| 001 | oai:gup.ub.gu.se/91543 | |
| 003 | SwePub | |
| 008 | 240528s2008 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:117692042 | |
| 024 | 7 | a https://gup.ub.gu.se/publication/915432 URI |
| 024 | 7 | a https://doi.org/10.1016/S0140-6736(08)61411-72 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1176920422 URI |
| 040 | a (SwePub)gud (SwePub)ki | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Sjölie, Anne Katrin4 aut |
| 245 | 1 0 | a Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. |
| 264 | 1 | c 2008 |
| 520 | a BACKGROUND: Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes. METHODS: We did a randomised, double-blind, parallel-group, placebo-controlled trial in 309 centres worldwide. We recruited normoalbuminuric, normotensive, or treated hypertensive people with type 2 diabetes with mild to moderately severe retinopathy and assigned them to candesartan 16 mg once a day or placebo. After a month, the dose was doubled to 32 mg once per day. Investigators and patients were unaware of the treatment allocation status. Progression of retinopathy was the primary endpoint, and regression was a secondary endpoint. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00252694. FINDINGS: 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps or more on the Early Treatment Diabetic Retinopathy Study scale. The risk of progression of retinopathy was non-significantly reduced by 13% in patients on candesartan compared with those on placebo (hazard ratio [HR] 0.87, 95% CI 0.70-1.08, p=0.20). Regression on active treatment was increased by 34% (1.34, 1.08-1.68, p=0.009). HRs were not attenuated by adjustment for baseline risk factors or changes in blood pressure during the trial. An overall change towards less severe retinopathy by the end of the trial was observed in the candesartan group (odds 1.17, 95% CI 1.05-1.30, p=0.003). Adverse events did not differ between the treatment groups. INTERPRETATION: Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy. | |
| 653 | a Adult | |
| 653 | a Aged | |
| 653 | a Angiotensin II Type 1 Receptor Blockers | |
| 653 | a adverse effects | |
| 653 | a therapeutic use | |
| 653 | a Benzimidazoles | |
| 653 | a adverse effects | |
| 653 | a therapeutic use | |
| 653 | a Diabetes Mellitus | |
| 653 | a Type 2 | |
| 653 | a complications | |
| 653 | a drug therapy | |
| 653 | a Diabetic Retinopathy | |
| 653 | a classification | |
| 653 | a drug therapy | |
| 653 | a etiology | |
| 653 | a Dose-Response Relationship | |
| 653 | a Drug | |
| 653 | a Double-Blind Method | |
| 653 | a Endpoint Determination | |
| 653 | a Female | |
| 653 | a Humans | |
| 653 | a Hypertension | |
| 653 | a complications | |
| 653 | a drug therapy | |
| 653 | a Hypoglycemic Agents | |
| 653 | a therapeutic use | |
| 653 | a Male | |
| 653 | a Middle Aged | |
| 653 | a Severity of Illness Index | |
| 653 | a Tetrazoles | |
| 653 | a adverse effects | |
| 653 | a therapeutic use | |
| 700 | 1 | a Klein, Ronald4 aut |
| 700 | 1 | a Porta, Massimo4 aut |
| 700 | 1 | a Orchard, Trevor4 aut |
| 700 | 1 | a Fuller, John4 aut |
| 700 | 1 | a Parving, Hans Henrik4 aut |
| 700 | 1 | a Bilous, Rudy4 aut |
| 700 | 1 | a Chaturvedi, Nish4 aut |
| 700 | 1 | a Wilhelmsen, Lars,d 1932u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xwilhl |
| 700 | 1 | a DIRECT Programme, Study Group4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin4 org |
| 773 | 0 | t Lancetg 372:9647, s. 1385-93q 372:9647<1385-93x 1474-547X |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/91543 |
| 856 | 4 8 | u https://doi.org/10.1016/S0140-6736(08)61411-7 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:117692042 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Sjölie, Anne Kat ...
- Klein, Ronald
- Porta, Massimo
- Orchard, Trevor
- Fuller, John
- Parving, Hans He ...
- visa fler...
- Bilous, Rudy
- Chaturvedi, Nish
- Wilhelmsen, Lars ...
- DIRECT Programme ...
- visa färre...
- Artiklar i publikationen
- Lancet
- Av lärosätet
- Göteborgs universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
